Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters.
[en] The erythroid abnormality in patients with myelodysplasia (MDS) is multifactorial, with ineffective erythropoiesis and poor in vitro progenitor response to erythropoietin (EPO). Serum EPO concentration is variable among patients for a given haemoglobin concentration. We studied 19 non-transfusion-dependent patients with MDS, and 13 healthy elderly control subjects in an attempt to define the factors governing variability in serum EPO and to further characterise the anaemia of MDS. Serum EPO concentration was appropriate for the degree of anaemia in 15/19 MDS patients, and was positively related to mean cell volume (MCV), mean cell haemoglobin (MCH), and percentage highly fluorescent reticulocytes (% HFR), but not to absolute or percentage reticulocyte count. Although the observed/predicted ratio for serum transferrin receptor (TfR) concentration was low in 12 of 19 MDS subjects, no relationship to haemoglobin concentration, reticulocytes or serum EPO was seen. Serum TfR was positively correlated with WBC and platelet counts. Serum TfR was higher in patients with sideroblastic anaemia than refractory anaemia. Standardized in vivo p50 was positively correlated to red cell 2,3 diphosphoglycerate concentration, although this was not the only factor influencing the oxygen dissociation curve. We conclude that effective erythroid output responsive to endogenous EPO drive in MDS is positively related to MCV, MCH and % HFR. Serum TfR may not represent effective output as precisely as % HFR, but may be proportional to total marrow erythropoietic activity.
Disciplines :
Hematology
Author, co-author :
Bowen, D. T.
Culligan, D.
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Kendall, R.
Willis, N.
Language :
English
Title :
Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters.
May SJ, Smith SA, Jacobs A, Williams A, Bailey-Wood R. The myelodysplastic syndrome: analysis of laboratory characteristics in relation to the FAB classification. Br J Haematol 1985;59:311-319.
Ricketts C, Jacobs A, Cavill I. Ferrokinetics and erythropoiesis in man: the measurement of effective erythropoiesis, ineffective erythropoiesis and red cell lifespan using 59Fe. Br J Haematol 1975;31:65-75.
Dormer P, Schalhorn A, Willmanns W, Hershko C. Erythroid and myeloid maturation patterns related to progenitor assessment in the myelodysplastic syndromes. Br J Haematol 1987;67:61-66.
Merchav S, Nielsen OJ, Rosenbaum H, Sharon R, Brenner B, Tatarsky I, Scigalla P, Wieczorek L. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes. Leukemia 1990;4:771-774.
Backx B, Breeders L, Touw I, Lowenberg B. Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia 1993;7:75-79.
Verhoef GEG, De Schouwer P, Ceuppens JL; Van Damme, J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992;6:1268-1272.
Aul C, Arning M, Runde V, Schneider W. Serum erythropoietin concentration in patients with myelodysplastic syndromes. Leuk Res 1991;15:571-575.
Jacobs A, Janowska-Wieczorek A, Caro J, Bowen DT, Lewis TC. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1989;73:36-39.
Bowen DT, Jacobs A, Cotes PM, Lewis TC. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes. Eur J Haematol 1990;44:30-32.
Bowen D, Culligan D, Jacobs A. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 1991;77:419-423.
Cazzola M, Poncio L, Beguin Y, Rosti V, Bergamaschi C, Liberato NL, Fregoni V, Nalli G, Barosi G, Ascari E. Subcutaneous erythropoietin for treatment of refractory anaemia in haematological disorders. Results of a phase I/II clinical trial. Blood 1992;79:29-37.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
Hillman R, Finch C. The misused reticulocyte. Br J Haematol 1969;17:313-314.
Rose ZB, Liebowitz J. Direct determination of a 2, 3 diphosphoglycerate. Ann Biochem 1970;35:177-180.
Willis N, Clapham MCC, Mapleson WW. Additional blood gas variables for the rational control of oxygen therapy with allowance for shifts in the oxygen dissociation curve. Br J Anaesth 1987;59:1160-1170.
Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990;75:102-107.
Beguin Y, demons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anaemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993;81:1067-1076.
Kendall RG, Chapman C, Hartley AE, Norfolk DR. Storage and preparation of samples for erythropoietin radioimmunoassay. Clin Lab Haematol 1991;13:189-196.
Bowen DT, Jacobs A. Primary acquired sideroblastic erythropoiesis in non-anaemic and minimally anaemic subjects. J Clin Pathol 1989;42:56-58.
Tichelli A, Gratwohl A, Driessen A, Mathys S, Pfefferkorn E, Regenass A, Schumacher P, SteblerC, Wernli M, Nissen C, Speck B. Evaluation of the Sysmex R-1000. An automated reticulocyte analyzer. Am J CMn Pathol 1990;93:70-78.
Lintula R. Red cell enzymes in myelodysplastic syndromes. Scand J Haematol 1986;36:56-59 (suppl).
Verhoef GEG, Zachee P, Ferrant A, Demuynck H, Sellesag D, Van Hove L, Deckers F, Boogaerts MA. Recombinant human erythropoietin for the treatment of anaemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann Haematol 1992;64:16-21.